Search PubMed⌕ Search

Biomedical subjects

A Hale

Publications and source records attributed to A Hale.

31 records · Page 2Linked to original sources
PubMed1993

Serum urate as a free radical scavenger in diabetics.

We have looked at the relationship between serum urate and the molar equivalent serum antioxidant capacity (MESA) in diabetic and normal individuals who attended St Bartholomew's Hospital diabetic clinic and BUPA Health Screening Centre, London, and have compared serum antioxidant capacity between the two groups. Sample response curves showed less serum antioxidant potential in diabetics than in nondiabetics, and a linear relationship between serum urate and MESA. Simple regression analysis gave a correlation coefficient of 0.9 (p < 0.0001). Significant differences between the two groups were found for both mean MESA values (p < 0.0001) and mean uric acid levels (p < 0.005).

Diabetes Mellitus, Type 1↗
PubMed1993

Fitness in a U.K. screening sample--a comparison with the Canadian population.

Fitness measurements were compared from approximately 12,000 men and 5,000 women attending the BUPA Health Screening Centre, London, with published Canadian levels. The mean (+/- SD) predicted VO2-max values in the BUPA group were 35.1 (+/- 9.2) and 30.0 (+/- 8.4) ml/kg/min for men and women aged 15-64 years, respectively. These compare with means of 44.1 and 34.3 in men and women of the same age in Canada. A comparison of flexibility measurements showed that in all age groups the BUPA subjects were less flexible than their Canadian counterparts, on average 28.7% and 25.1% lower for men and women, respectively. Comparison of grip strength showed BUPA values to be on average 8.1% lower in men and 9.5% lower in women than the Canadian levels. Analysis of variance showed that the fitness measurements reflect the recorded physical activity in the BUPA sample, and in particular the predicted VO2-max and flexibility exhibit linear relationships with age and exercise levels.

Adolescent↗
PubMed1992

Serum urate, serum glucose and diabetes.

We have studied the relationship between serum glucose and urate in 260,699 men and 214,118 women from Sweden, and 140,084 men and 30,653 women from the UK. We found an increase in mean serum urate with increasing glucose concentrations up to 7.0 mmol/L in men and 9.0 mmol/L in women. Thereafter increasing glucose values were accompanied by a statistically significant decrease in urate concentrations. This fall was particularly marked in younger subjects. We believe this may have important implications for the free radical status of diabetics.

Adult↗
PubMedDate not supplied

Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993).

Forty-eight dogs with histologically confirmed appendicular osteosarcoma (OSA) entered a prospective clinical trial evaluating treatment with amputation and up to 4 doses of carboplatin given every 21 days. The median disease-free interval (DFI) was 257 days, with 31.2% of the dogs disease-free at 1 year. The median survival time was 321 days, with 35.4% of the dogs alive at 1 year. Dogs with proximal humeral OSA had shorter DFI (P = .016) and survival (P = .037) times than dogs with OSA at other locations. Dogs with lower body weights ( < 40 kg) had longer DFI (P = .0056) and survival (P = .007) times than larger dogs. Survival times for dogs that received carboplatin were statistically longer than those previously reported for amputation alone (P < .001). DFI and survival times are similar to those previously reported for 2 to 4 doses of cisplatin. Carboplatin appears to be a well-tolerated chemotherapeutic drug that can be given safely every 21 days at a dose of 300 mg/m2. Neutropenia was the dose-limiting toxicity in this study.

Amputation, Surgical↗